Advanced Regenerative Medicine Review Committee
Approves Clinical Research Implementation Plans

Clinical research on advanced regenerative medicine, involving immunocyte administration, will be conducted for patients with advanced hepatocellular carcinoma and diffuse large B-cell lymphoma (DLBCL).


The Ministry of Health and Welfare announced on July 24 that at the 8th Advanced Regenerative Medicine and Advanced Biopharmaceuticals Review Committee meeting held the previous day, two clinical research implementation plans were approved as appropriate.


The committee reviewed a total of six implementation plans submitted by regenerative medicine institutions, determining two as appropriate and four as inappropriate.


Two Clinical Trials on Cell Therapy for Hepatocellular Carcinoma and Lymphoma to Be Conducted View original image

The first study is a medium-risk cell therapy clinical trial for patients with advanced hepatocellular carcinoma, in which standard anticancer therapy, radiotherapy, and natural killer cell (NK cell) therapy are concurrently administered.


Currently, the primary treatment for advanced hepatocellular carcinoma consists of a combination of the immunotherapy agent atezolizumab and the targeted therapy bevacizumab. However, some patients do not respond adequately or experience only a short duration of effectiveness, and those with accompanying liver cirrhosis may find it difficult to tolerate systemic anticancer therapy.


The research team will isolate NK cells from the patient’s peripheral blood, proliferate and activate them using supporting cells and interleukin (IL)-2, and then reinfuse them into the patient. The study will evaluate safety, objective response rate, disease control rate, and progression-free survival while combining standard therapy and radiotherapy.


The second study targets DLBCL patients who have achieved complete remission after first-line induction therapy with R-CHOP but are at high risk of relapse. This is a medium-risk, multi-center clinical study in which cytokine-induced killer cells (CIK), derived from the patient's own blood, are administered repeatedly.


DLBCL has a poor prognosis in cases of relapse, but there are limited maintenance therapy options to prevent recurrence in high-risk patients. The research team aims to determine whether CIK cell administration can eliminate any remaining cancer cells and reduce the likelihood of relapse.



Kim Dongik, chair of the Advanced Regenerative Medicine and Advanced Biopharmaceuticals Review Committee, stated, "We will do our best to ensure safe clinical research by prioritizing patient safety and conducting impartial, expert reviews based on scientific evidence and ethics."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing